Hu Wenwei, Wu Chen, Li Xiaodong, Zheng Zhuojun, Xie Quanqin, Deng Xu, Jiang Jingting, Wu Changping
Department of Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
Department of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
Oncotarget. 2017 May 23;8(21):35116-35123. doi: 10.18632/oncotarget.16627.
This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemotherapy patients and healthy subjects, respectively. sIL-33 levels were 131.9 (95% CI 105.9-184.9) pg/mL, 95.1 (95% CI 70.8-140.2) pg/mL and 95.7 (95% CI 73.3-114.3) pg/mL in pre-chemotherapy patients, post-chemotherapy patients and controls, respectively. The sIL-33 level in pre-chemotherapy patients was significantly higher than that in both post-chemotherapy patients and controls (P < 0.001 and P < 0.001, respectively). There was no statistically significant difference between the sIL-33 levels in post-chemotherapy patients and controls (P > 0.05). PFS in patients with the decline extent > 30.1% (median PFS not reached) was statistically significant longer than that (median PFS 7 months, 95% CI 1.569 - 12.431) in patients with the decline extent ≤ 30.1% (P = 0.003). The decline extent of sIL-33 level (> 30.1%) was associated with longer PFS (P = 0.006). Distant metastasis was associated with the decline extent of sIL-33 level (P = 0.034). The decline extent of sIL-33 after chemoresistance could be regarded as a predictor of the PFS of GC patients.
本研究旨在评估胃癌（GC）患者血清白细胞介素-33（sIL-33）水平与无进展生存期（PFS）之间的关联。共纳入62例晚期GC患者和32例健康受试者。分别检测了化疗前患者、化疗后患者和健康受试者的sIL-33水平。化疗前患者、化疗后患者和对照组的sIL-33水平分别为131.9（95%可信区间105.9 - 184.9）pg/mL、95.1（95%可信区间70.8 - 140.2）pg/mL和95.7（95%可信区间73.3 - 114.3）pg/mL。化疗前患者的sIL-33水平显著高于化疗后患者和对照组（分别为P < 0.001和P < 0.001）。化疗后患者和对照组的sIL-33水平之间无统计学显著差异（P > 0.05）。下降幅度> 30.1%（中位PFS未达到）的患者的PFS在统计学上显著长于下降幅度≤ 30.1%的患者（中位PFS 7个月，95%可信区间1.569 - 12.431）（P = 0.003）。sIL-33水平的下降幅度（> 30.1%）与更长的PFS相关（P = 0.006）。远处转移与sIL-33水平的下降幅度相关（P = 0.034）。化疗耐药后sIL-33的下降幅度可被视为GC患者PFS的一个预测指标。
